Depiperazine-DM3189

Depiperazine-DM3189 is a derivative of LDN193189 (HY-12071) . LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva[1][2][3].

Product Specifications

CAS Number

[1062368-55-1]

Product Name Alternative

Depiperazine-LDN-193189

Target

Drug Derivative; TGF-beta/Smad

Related Pathways

Others; Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Cancer

Smiles

C1(C2=C3N=CC(C4=CC=CC=C4)=CN3N=C2)=CC=NC5=CC=CC=C15

Molecular Formula

C21H14N4

Molecular Weight

322.36

References & Citations

[1]Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med, 2008, 14 (12), 1363-1369. |[2]Daniel Horbelt, et al. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J Biol Chem. 2015 Feb 6;290 (6) :3390-404. |[3]Julien Vollaire, et al. The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice. Front Pharmacol. 2019 Jun 19;10:667.